Mesothelin (MSLN) is overexpressed in various malignancies,makingit a promising target for molecular imaging and therapeutic strategies.Anti-MSLN VH-Fc fusion proteins show high tumor uptake as comparedwith monoclonal antibodies; however, elevated accumulation in Fc-richorgans (liver, spleen) can compromise tumor-to-background ratios andlimit clinical applicability. Here, MSLN is linked to neoplasm.